ZyVersa Therapeutics, Inc. 8-K

What Happened
ZyVersa Therapeutics, Inc. (ZVSA) filed an 8-K on July 10, 2026 reporting that independent director Min Chul Park, Ph.D., resigned from the Board and its Compensation and Nominating & Corporate Governance Committees effective July 8, 2026 for personal reasons (not due to any disagreement with the company). The filing also discloses that the Board and management have begun and are continuing to explore cost-cutting measures to preserve cash while seeking additional capital.

Key Details

• Director resignation: Min Chul Park, Ph.D., resigned effective July 8, 2026; resignation accepted by the Board; reason cited as personal and not a disagreement with the company.
• Executive pay reductions: CEO Stephen Glover and CFO Peter Wolfe voluntarily agreed to reduced compensation to support the company’s limited cash resources.
• Cost-cutting options under consideration: potential divestiture or sale of product candidates VAR 200 or IC 100; headcount reductions; lowering public company expenses, including possible suspension of SEC filing obligations under Rule 12h‑3 (“going dark”); sale of the company or assets; restructuring or reorganization.
• Forward-looking caution: the company warns these actions are forward-looking and subject to risks described in its 2025 Form 10-K and 2026 Form 10-Q.

Why It Matters
These disclosures indicate ZyVersa is under financial pressure and taking steps to extend its runway while seeking financing. For investors, key takeaways are that management has taken pay cuts and the company may pursue asset sales, workforce reductions, or even suspend public reporting—each of which could materially affect the company’s operations, development programs (VAR 200, IC 100), and investor access to information. The director’s departure was stated to be for personal reasons and not related to a dispute with the company.